Redhill Biopharma Ltd. current report, Q2 FY2021

Full document

Redhill Biopharma Ltd. Form 6-K Summary

Business Context and Reporting Period

This Form 6-K, filed on June 17, 2021, serves as a notice and proxy statement for Redhill Biopharma Ltd.'s Annual General Meeting of Shareholders scheduled for July 26, 2021. The filing incorporates by reference the notice and proxy statement for the meeting. The Company is a foreign private issuer based in Tel Aviv, Israel, with shares traded on NASDAQ. The record date for shareholders entitled to vote is June 17, 2021.

Key Financial Metrics

The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the current period. It references the Company's financial statements for the fiscal year ended December 31, 2020, which shareholders will have an opportunity to review at the meeting. The only specific financial data points provided relate to proposed compensation and equity grants:

  • Outstanding Shares: 467,200,134 Ordinary Shares (represented by 46,720,013 ADSs) as of June 16, 2021.
  • Proposed Director Fees: Annual cash retainer of $40,000; committee fees ranging from $1,500 to $10,000; chairperson fees at 50% or 10% premiums.
  • Proposed Executive Compensation: Chief Commercial Officer (Rick D. Scruggs) salary increase to $627,000 and a $200,000 annual bonus.
  • Indemnification Cap: Proposed increase from $5,000,000 to $10,000,000 (or 25% of shareholders' equity, whichever is greater).

Material Changes and Proposals

The filing outlines 13 proposals for shareholder approval, representing material changes to corporate governance and compensation structures:

  1. Auditor Appointment: Re-appointment of Kesselman & Kesselman (PwC member) for 2021.
  2. Board Elections: Re-election of Ofer Tsimchi and Eric Swenden; election of Alessandro Della Chà for three-year terms.
  3. Director Compensation: Adoption of an annual retainer model for directors, effective retroactively to January 1, 2021.
  4. Compensation Policy Amendments: Updates to allow annual retainers, adjust bonus conditions, and modify minimum option exercise prices to the closing share price on the date of approval.
  5. Indemnification: Increase in the maximum prospective indemnification amount for officers and directors to $10,000,000.
  6. Equity Plan Amendment: Change the automatic increase of the option pool from an annual basis to a quarterly basis (15% of outstanding shares).
  7. Equity Grants:
    • Directors: 18,000 ADS options each (exercise price $7.08 or closing price at meeting).
    • CEO (Dror Ben-Asher): 110,000 ADS options (exercise price $7.08).
    • CCO (Rick Scruggs): 75,000 ADS options.
    • U.S. Directors: Additional options (9,856 and 7,485 ADSs) to compensate for higher exercise prices on previously repriced options due to U.S. tax consequences.
  8. Executive Employment Terms:
    • Approval of salary increase and $200,000 bonus for CCO Rick Scruggs.
    • Amended employment terms for Rick Scruggs and Dr. June Almenoff (CSO) including 12 months' severance pay upon termination without cause, exceeding the standard policy requirement.

Outlook, Risks, and Management Commentary

Management highlights the acquisition of Movantik and the launch of Talicia as key achievements in 2020, justifying the proposed bonus for the Chief Commercial Officer. The Company notes that the proposed severance packages for executives exceed the minimums required by the Compensation Policy and Israeli law, necessitating shareholder approval. The filing states the Company is currently unaware of any other matters to be raised at the meeting. No specific forward-looking guidance on revenue or clinical trial timelines is provided in this document.

Investor Verification Checklist

  • Verify the Company's cash position and burn rate in the most recent Form 20-F to assess the impact of increased executive compensation and equity dilution.
  • Review the specific terms of the "repriced options" mentioned in Proposal 10 to understand the tax implications driving the additional grants to U.S. directors.
  • Confirm the current market price of ADSs relative to the proposed exercise prices ($7.08) to evaluate the immediate value of the equity grants.
  • Assess the financial impact of the proposed $10,000,000 indemnification cap increase relative to the Company's total assets.
  • Check the voting requirements for Proposals 4, 5, 9, 12, and 13, which require a majority of non-controlling shareholders without a personal interest.